Dr. Reddy's Laboratories Ltd - Company Profile
Powered by 
All the data and insights you need on Dr. Reddy's Laboratories Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Dr. Reddy's Laboratories Ltd Strategy Report
- Understand Dr. Reddy's Laboratories Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company that manufactures and markets generic formulations, active pharmaceutical ingredients (APIs), biosimilars and proprietary products. The company’s generic products are indicated for the treatment of gastrointestinal disorders, various cancer types, pain, cardiovascular diseases, central nervous system disorders, infectious diseases, and pediatric diseases. The company also develops and markets generic biosimilar products. Its pipeline includes New Chemical Entities (NCEs) that focus on the treatment of metabolic disorders, bacterial infections, pain, and inflammation. The company markets products in the US, Europe, Latin America, and Asia. Dr. Reddy's is headquartered in Hyderabad, Telangana, India.
Headquarters
India
Address
8-2-337, Road No.3 Banjara Hills, Hyderabad, Telangana, 500034
Website
www.drreddys.com
Telephone
91 40 49002900
No of Employees
24,832
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DRREDDY (NSE)
Revenue (2022)
$3.1B
14.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
106.5%
(2022 vs 2021)
Market Cap*
$12.0B
Net Profit Margin (2022)
XYZ
80.4%
(2022 vs 2021)
* As of and is in US$
Dr. Reddy's Laboratories Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Generic Biosimilars | Contract Manufacturing | OMEZ |
| Generic Small-Molecule Drugs | Custom Pharma Services | Stamlo |
| Active Pharma Ingredients | Nise | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company signed a license agreement with Pharmazz to sell a first-in-class innovative drug Centhaquine in India. |
| 2024 | Contracts/Agreements | In March, the company entered into a collaboration with Sanofi Healthcare India to distribute SHIPL vaccine brands across India. |
| 2024 | Contracts/Agreements | In January, the company collaborated with Edity Therapeutics to form novel cell therapy medicines by applying Edity’s proprietary delivery platform. |
Competitor Comparison
| Key Parameters | Dr. Reddy's Laboratories Ltd | Pfizer Inc | Bayer AG | Novartis AG | GSK plc |
|---|---|---|---|---|---|
| Headquarters | India | United States of America | Germany | Switzerland | United Kingdom |
| City | Hyderabad | New York | Leverkusen | Basel | Brentford |
| State/Province | Telangana | New York | Nordrhein-Westfalen | - | England |
| No. of Employees | 24,832 | 88,000 | 99,723 | 76,057 | 70,212 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| K. Satish Reddy | Chairman | Executive Board | 2015 | 55 |
| G V Prasad | Managing Director; Co-Chairman | Executive Board | 2021 | 62 |
| Erez Israeli | Chief Executive Officer | Senior Management | 2018 | 56 |
| Parag Agarwal | Chief Financial Officer | Senior Management | 2020 | 57 |
| Patrick Aghanian | Chief Executive Officer - European Generics | Senior Management | 2019 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward